ScreenerHero
PHARMPharming Group N.V.
AMS · NL · Healthcare · Biotechnology · pharming.com
1.016EUR+2.07%Mkt Cap: 781.64M $P/E: 101.60

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. Th…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap781.64M $
Enterprise Value716.89M $
Revenue (TTM)398.35M $
Gross Profit359.38M $
Net Income (TTM)3.10M $
Revenue/Share0.5674 USD
Last Price1.016 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees407
CountryNL
SectorHealthcare
IndustryBiotechnology
ISINNL0010391025
Valuation
P/E (Trailing)101.60
P/E (Forward)45.74
PEG—
EV/EBITDA20.06
EV/Revenue1.80
P/S1.92
P/B3.01
EPS (TTM)0.01
EPS (Forward)0.02
52W Range
0.833819% of range1.818
52W High1.818 EUR
52W Low0.8338 EUR
Profitability
Gross Margin87.90%
Oper. Margin1.46%
EBITDA Margin8.97%
Profit Margin0.76%
ROE1.03%
ROA0.57%
Growth
Revenue Growth-3.20%
Earnings Growth-62.90%
Cash Flow & Leverage
Operating CF59.47M $
CapEx (TTM)820.65K $
FCF Margin10.28%
FCF Yield5.24%
Net Debt-48.90M $
Net Debt/EBITDA-1.37
Balance Sheet
Debt/Equity0.42
Current Ratio3.01
Quick Ratio2.31
Book Value/Sh0.3305 EUR
Cash/Share0.2240 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateMar 5, 2013
Analyst Consensus
Rating—
Target (Mean)2.240 EUR
Upside (mean)+120.5%
Target Range1.968 EUR – 2.411 EUR
€1.968+120.5% to mean€2.411
# Analysts3
Ownership
Shares Out.707.78M
Float696.57M
Insiders1.95%
Institutions23.15%
Technical
SMA 501.099 (-7.5%)
SMA 2001.316 (-22.8%)
Beta0.06
S&P 52W Chg18.16%
Avg Vol (30d)11.02M
Avg Vol (10d)9.86M
Technical Indicators
RSI (14)44.4
MACD-0.0321
MACD Signal-0.0434
MACD Hist.+0.0114
BB Upper1.155 EUR
BB Middle0.9931 EUR
BB Lower0.8310 EUR
BB Width32.66%
ATR (14)0.0414 EUR
Vol Ratio (20d)0.58x